QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC

Published:2024-09 Issue:9 Volume:5 Page:1164-1177.e3
ISSN:2666-6340
Container-title:Med
language:en
Short-container-title:Med

Author:

Bando Hideaki,Kotani Daisuke,Satake Hironaga,Hamaguchi Tetsuya,Shiozawa Manabu,Kotaka Masahito,Masuishi Toshiki,Yasui Hisateru,Kagawa Yoshinori,Komatsu Yoshito,Oki Eiji,Yamamoto Yoshiyuki,Kawakami Hisato,Misumi Toshihiro,Taniguchi Hiroya,Yamazaki Kentaro,Muro Kei,Yoshino Takayuki,Kato Takeshi,Tsuji Akihito

Funder

Chugai Pharmaceutical

Publisher

Elsevier BV

Reference22 articles.

1. Global colorectal cancer burden in 2020 and projections to 2040;Xi;Transl. Oncol.,2021

2. Treatment of Metastatic Colorectal Cancer: ASCO Guideline;Morris;J. Clin. Oncol.,2023

3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann. Oncol.,2016

4. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Yoshino;Ann. Oncol.,2018

5. Individual patient data meta-analysis of Folfoxiri plus Bevacizumab versus doublets plus Bevacizumab as initial therapy of unresectable metastatic colorectal cancer;Cremolini;J. Clin. Oncol.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP